Early onset post‐transplant lymphoproliferative disease is associated with allograft localization
- 22 April 2005
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 19 (3) , 327-334
Abstract
Abstract: Post‐transplant lymphoproliferative disease (PTLD) is a major complication after solid organ transplantation. We analyzed incidence, patient characteristics, clinical presentation, and prognostic factors for treatment outcome and survival of PTLD patients transplanted at our center. Records from adult kidney and lung transplant recipients, transplanted between January 1985 and December 2002 with a histologically confirmed diagnosis of PTLD, were retrieved. Histology was reviewed and prognostic factors for treatment outcome were evaluated by multivariable analysis. Of 1354 kidney and 206 lung transplants, PTLD was diagnosed in 40 transplant recipients (2.6%). Lung transplant recipients had a significantly higher incidence of PTLD (8.3%) than kidney transplant recipients (1.7%). Sites of presentation were highly heterogeneous. Notably, PTLD localized in the allograft occurred significantly earlier after transplantation than PTLD localized outside the allograft (p = 0.001). This was true for lung (p = 0.006) as well as for kidney transplant recipients (p = 0.03). In multivariable Cox regression, performance status (p = 0.01) and advanced stage (p = 0.04) were factors negatively predictive for response to first‐line treatment. Only performance status remained as negative predictive factor for survival (p = 0.002) and freedom from tumor progression (p = 0.01). In conclusion, the allograft is significantly more often involved as primary site of PTLD presentation during the first post‐transplant year. This may have clinical consequences and give new insights in pathogenesis of PTLD. Performance status and stage are important risk factors for outcome of PTLD.Keywords
This publication has 32 references indexed in Scilit:
- A single-centre experience of post-renal transplant lymphoproliferative disorderTransplant International, 2003
- Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1Transplantation, 2002
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMABTransplantation, 2002
- Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patientsBlood, 2001
- EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1Transplantation, 2000
- EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1999
- Pretransplantation Assessment of the Risk of Lymphoproliferative DisorderClinical Infectious Diseases, 1995
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- LYMPHOPROLIFERATIVE DISORDER MASQUERADING AS REJECTION IN LIVER TRANSPLANT RECIPIENTS-AN EARLY AGGRESSIVE TUMOR WITH TYPICAL PRESENTATIONTransplantation, 1992
- Chronic Antigenic Stimulation from the Graft as a Possible Oncogenic Factor after Renal TransplantScandinavian Journal of Urology and Nephrology, 1983